Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term tolerability and durable LDL-C lowering with AMG 145 in hyperlipidemia
2011-003827-37Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hyperlipidemia comparing AMG 145 with Placebo (2 arms). Primary endpoint: Percent change from baseline in LDL-C at week 52. Started Nov 2011; status: completed.
02
Drugs
evolocumab
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on 2011-003827-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003827-37.